Equillium (NASDAQ:EQ) PT Raised to $5.00 at HC Wainwright

Equillium (NASDAQ:EQ) had its price target lifted by equities researchers at HC Wainwright from $4.00 to $5.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price target suggests a potential upside of 114.59% from the stock’s previous close. HC Wainwright also issued estimates for Equillium’s Q1 2025 earnings at ($0.20) EPS, Q2 2025 earnings at ($0.20) EPS, Q3 2025 earnings at ($0.20) EPS, Q4 2025 earnings at ($0.21) EPS and FY2025 earnings at ($0.82) EPS.

Equillium Trading Up 6.9 %

Shares of NASDAQ EQ opened at $2.33 on Tuesday. The firm has a market cap of $82.16 million, a price-to-earnings ratio of -5.97 and a beta of 1.62. The stock has a fifty day simple moving average of $2.10 and a two-hundred day simple moving average of $1.16. Equillium has a 1-year low of $0.45 and a 1-year high of $3.25.

Institutional Investors Weigh In On Equillium

Institutional investors have recently made changes to their positions in the stock. Decheng Capital LLC purchased a new stake in shares of Equillium in the fourth quarter worth $3,215,000. JPMorgan Chase & Co. purchased a new stake in shares of Equillium in the first quarter worth $1,182,000. Renaissance Technologies LLC raised its position in shares of Equillium by 913.5% in the second quarter. Renaissance Technologies LLC now owns 392,231 shares of the company’s stock worth $294,000 after buying an additional 353,531 shares in the last quarter. State Street Corp raised its position in shares of Equillium by 13.2% in the first quarter. State Street Corp now owns 56,220 shares of the company’s stock worth $177,000 after buying an additional 6,564 shares in the last quarter. Finally, Integrated Wealth Concepts LLC raised its position in shares of Equillium by 56.7% in the fourth quarter. Integrated Wealth Concepts LLC now owns 31,339 shares of the company’s stock worth $33,000 after buying an additional 11,339 shares in the last quarter. Hedge funds and other institutional investors own 27.05% of the company’s stock.

Equillium Company Profile

Equillium, Inc, a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis.